Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation
- PMID: 26496237
- PMCID: PMC4966519
- DOI: 10.1080/19420862.2015.1110660
Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation
Abstract
The pH-dependent antigen binding antibody, termed a recycling antibody, has recently been reported as an attractive type of second-generation engineered therapeutic antibody. A recycling antibody can dissociate antigen in the acidic endosome, and thus bind to its antigen multiple times. As a consequence, a recycling antibody can neutralize large amounts of antigen in plasma. Because this approach relies on histidine residues to achieve pH-dependent antigen binding, which could limit the epitopes that can be targeted and affect the rate of antigen dissociation in the endosome, we explored an alternative approach for generating recycling antibodies. Since calcium ion concentration is known to be lower in endosome than in plasma, we hypothesized that an antibody with antigen-binding properties that are calcium-dependent could be used as recycling antibody. Here, we report a novel anti-interleukin-6 receptor (IL-6R) antibody, identified from a phage library that binds to IL-6R only in the presence of a calcium ion. Thermal dynamics and a crystal structure study revealed that the calcium ion binds to the heavy chain CDR3 region (HCDR3), which changes and possibly stabilizes the structure of HCDR3 to make it bind to antigen calcium dependently (PDB 5AZE). In vitro and in vivo studies confirmed that this calcium-dependent antigen-binding antibody can dissociate its antigen in the endosome and accelerate antigen clearance from plasma, making it a novel approach for generating recycling antibody.
Keywords: Antibody engineering; antigen clearance; antigen dissociation; calcium ion; recycling antibody.
Figures






Similar articles
-
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.Nat Biotechnol. 2010 Nov;28(11):1203-7. doi: 10.1038/nbt.1691. Epub 2010 Oct 17. Nat Biotechnol. 2010. PMID: 20953198
-
Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.PLoS One. 2013 May 7;8(5):e63236. doi: 10.1371/journal.pone.0063236. Print 2013. PLoS One. 2013. PMID: 23667591 Free PMC article.
-
Phage display assisted discovery of a pH-dependent anti-α-cobratoxin antibody from a natural variable domain library.Protein Sci. 2023 Dec;32(12):e4821. doi: 10.1002/pro.4821. Protein Sci. 2023. PMID: 37897425 Free PMC article.
-
[Advance in research on recycling antibody].Sheng Wu Gong Cheng Xue Bao. 2019 Feb 25;35(2):183-194. doi: 10.13345/j.cjb.180202. Sheng Wu Gong Cheng Xue Bao. 2019. PMID: 30806048 Review. Chinese.
-
pH-dependent antigen-binding antibodies as a novel therapeutic modality.Biochim Biophys Acta. 2014 Nov;1844(11):1943-1950. doi: 10.1016/j.bbapap.2014.08.003. Epub 2014 Aug 12. Biochim Biophys Acta. 2014. PMID: 25125373 Review.
Cited by
-
Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.MAbs. 2024 Jan-Dec;16(1):2383013. doi: 10.1080/19420862.2024.2383013. Epub 2024 Jul 25. MAbs. 2024. PMID: 39051531 Free PMC article.
-
Targeting FcRn to Generate Antibody-Based Therapeutics.Trends Pharmacol Sci. 2018 Oct;39(10):892-904. doi: 10.1016/j.tips.2018.07.007. Epub 2018 Aug 22. Trends Pharmacol Sci. 2018. PMID: 30143244 Free PMC article. Review.
-
In Translation: FcRn across the Therapeutic Spectrum.Int J Mol Sci. 2021 Mar 17;22(6):3048. doi: 10.3390/ijms22063048. Int J Mol Sci. 2021. PMID: 33802650 Free PMC article. Review.
-
A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.Eur J Pharm Sci. 2019 Oct 1;138:105032. doi: 10.1016/j.ejps.2019.105032. Epub 2019 Aug 5. Eur J Pharm Sci. 2019. PMID: 31394258 Free PMC article.
-
Fifty years of monoclonals: the past, present and future of antibody therapeutics.Nat Rev Immunol. 2025 Aug 7. doi: 10.1038/s41577-025-01207-9. Online ahead of print. Nat Rev Immunol. 2025. PMID: 40775487 Review.
References
-
- Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-8; PMID:16151394; http://dx.doi.org/ 10.1038/nbt0905-1073 - DOI - PubMed
-
- Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; http://dx.doi.org/ 10.1093/protein/gzq009 - DOI - PubMed
-
- Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. mAbs 2011; 3:422-30; PMID:22048693; http://dx.doi.org/ 10.4161/mabs.3.5.16983 - DOI - PMC - PubMed
-
- Rajpal A, Beyaz N, Haber L, Cappuccilli G, Yee H, Bhatt RR, Takeuchi T, Lerner RA, Crea R. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci U S A 2005; 102:8466-71; PMID:15939870; http://dx.doi.org/ 10.1073/pnas.0503543102 - DOI - PMC - PubMed
-
- Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al.. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203-7; PMID:20953198; http://dx.doi.org/ 10.1038/nbt.1691 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials